We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
The current 0ABW market cap is 0. The company's latest EPS is SEK and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 82.56M | 40.66M | 38.5M | 22.6M | 57.6M |
| Operating Income | -66.61M | -178.15M | -105.6M | -197M | -320.2M |
| Net Income | -61.42M | -179.12M | -104.5M | -193.8M | -326.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 270.07M | 893.97M | 569.3M | 561.1M | 760.2M |
| Total Liabilities | 25.2M | 264.34M | 42.3M | 54.9M | 214.6M |
| Total Equity | 244.88M | 629.63M | 527M | 506.2M | 545.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -62.64M | -134.64M | -130.1M | -173.5M | -278.4M |
| Investing | N/A | -59.54M | -6M | -1.7M | N/A |
| Financing | 86.72M | 228.41M | -8.9M | 155.7M | 458.9M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 292.57M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Egetis Therapeutics Ab (publ) |
| Address |
grev turegatan 11 c stockholm 114 46 |
| Website | https://www.egetis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
